Pfizer has agreed to acquire biopharmaceutical company Vicuron Pharmaceuticals for $1.9 billion in a move to expand its offerings of anti-infective products.
Vicuron, based in King of Prussia, Pa., has two products currently under new drug application review at the FDA.
The products are anidulafungin for fungal infections and dalbavancin for skin and soft tissue infections. Both have shown positive results in late-stage studies, according to published reports.
Pfizer to buy Vicuron Pharmaceuticals for $1.9 billion
Pfizer has agreed to acquire biopharmaceutical company Vicuron Pharmaceuticals for $1.9 billion in a move to expand its offerings of anti-infective products.
